Q-omics provides the consensus-scored LRRC14B profile across patient tissues and cancer cell-line models. LRRC14B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, LRRC14B is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LRRC14B RNA expression shows 14,736 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where LRRC14B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC14B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC14B survival associations across molecular data types. LRRC14B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC14B RNA expression–survival associations across cancer types. High LRRC14B expression shows unfavorable associations in STAD, CESC, UVM and THCA, but favorable associations in SKCM and UCEC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for LRRC14B RNA expression.
This table summarizes LRRC14B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LRRC14B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC14B shows lower tumor expression in HNSC and higher tumor expression in KIRC, KICH, LUSC, BRCA and LUAD. The KIRC box plot shows higher LRRC14B RNA expression in tumor versus normal tissue (log2 FC = +0.483, t-test p < 0.001).
This table shows molecular features associated with LRRC14B in patient tissues and cancer cell lines. In patient samples, LRRC14B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC14B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
